<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489944</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000551559</org_study_id>
    <secondary_id>POHA-0604</secondary_id>
    <nct_id>NCT00489944</nct_id>
  </id_info>
  <brief_title>Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma</brief_title>
  <official_title>A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Diego Pacific Oncology &amp; Hematology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor&#xD;
      and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such&#xD;
      as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells or by stopping them from dividing. Giving sunitinib together with&#xD;
      tamoxifen and cisplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving sunitinib&#xD;
      together with tamoxifen and cisplatin works in treating patients with high-risk ocular&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of adjuvant sunitinib malate, tamoxifen citrate, and cisplatin on&#xD;
           disease-free survival and overall survival of patients with high-risk ocular melanoma&#xD;
           who have undergone primary therapy.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive oral sunitinib malate once daily on days 1-21, oral tamoxifen citrate twice&#xD;
      daily on days 1-7, and cisplatin IV on days 2 and 3. Treatment repeats every 28 days for 4&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intraocular Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of ocular melanoma&#xD;
&#xD;
               -  High-risk disease, defined by any of the following:&#xD;
&#xD;
                    -  Large choroidal tumors with a basal diameter ≥ 16 mm and/or tumor thickness&#xD;
                       ≥ 10 mm (T3)&#xD;
&#xD;
                    -  Extrascleral extension (T4)&#xD;
&#xD;
                    -  Ciliary body involvement&#xD;
&#xD;
                    -  Epithelioid cell type only&#xD;
&#xD;
          -  Have undergone appropriate primary treatment for ocular melanoma&#xD;
&#xD;
          -  No measurable metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,200/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Pancreatic enzymes normal&#xD;
&#xD;
          -  Thyroid function normal or stable on replacement therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 50% by MUGA or ECHO&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring medication&#xD;
&#xD;
          -  No history of pulmonary disease requiring supplemental oxygen&#xD;
&#xD;
          -  No dyspnea at rest&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No chronic underlying immunodeficiency disease&#xD;
&#xD;
          -  No other serious illness that would preclude patient safety, in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  No other cancer within the past 5 years except nonmelanoma skin cancer or cervical&#xD;
             cancer&#xD;
&#xD;
          -  No thromboembolic disease within the past 6 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior sunitinib malate, tamoxifen citrate, or cisplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy, radiotherapy, or surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward F. McClay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Pacific Oncology &amp; Hematology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F. McClay, MD</last_name>
      <phone>760-452-3340</phone>
      <email>emcclay@pacificoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>epithelioid cell intraocular melanoma</keyword>
  <keyword>stage IIB intraocular melanoma</keyword>
  <keyword>stage IIIA intraocular melanoma</keyword>
  <keyword>stage IIIB intraocular melanoma</keyword>
  <keyword>stage IIIC intraocular melanoma</keyword>
  <keyword>stage IV intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

